Inventor · disambiguated record
Daniel Parks
Also filed as: PARKS DANIEL · PARKS DANIEL J
19 granted patents·14 pending applications·33 citations·filing 2002–2024
91Inventor score
Files withPROTEOSTASIS THERAPEUTICS INC14JANSSEN PHARMACEUTICA NV9LU TIANBAO3PLAYER MARK R3KINETA INC1
Top patents by PatentIndex Score
33 records- 0193US10550106B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Granted Feb 4, 2020·9 cites·13 claims
- 0288US2024109922A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0387US10662207B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted May 26, 2020·4 cites·27 claims
- 0487US2024368198A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0582US9193736B2PDE 10a inhibitors for the treatment of type II diabetesJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Nov 24, 2015·7 cites·14 claims
- 0676US11136313B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2019·Granted Oct 5, 2021·1 cites·24 claims
- 0775US10899751B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted Jan 26, 2021·1 cites·17 claims
- 0873US12319698B2Proteasome activity enhancing compoundsKINETA INC·Filed 2022·Granted Jun 3, 2025·0 cites·22 claims
- 0973US10118900B2Benzimidazole derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Nov 6, 2018·1 cites·14 claims
- 1072US11248010B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Feb 15, 2022·0 cites·11 claims
- 1172US9718820B2Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Aug 1, 2017·1 cites·19 claims
- 1270US8680098B2Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulatorsPLAYER MARK R·Filed 2011·Granted Mar 25, 2014·2 cites·24 claims
- 1368US7067512B2Substituted 1,4-benzodiazepines and uses thereofLU TIANBAO·Filed 2002·Granted Jun 27, 2006·5 cites·33 claims
- 1467US2022227739A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1565US7115598B2Substituted 1,4-diazepines and uses thereofORTHO MCNEIL PHARM INC·Filed 2004·Granted Oct 3, 2006·2 cites·62 claims
- 1663US11560385B2Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·0 cites·21 claims
- 1759US9023846B2Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted May 5, 2015·0 cites·11 claims
- 1858US2019031618A1Benzimidazole derivatives useful as cb-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2018·Application pending·0 cites
- 1957US2025129067A1Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereofPROGENTOS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2051US9409915B2Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Aug 9, 2016·0 cites·14 claims
- 2150US8232409B2Heterocyclic benzimidazoles as TRPM8 modulatorsPLAYER MARK R·Filed 2009·Granted Jul 31, 2012·0 cites·40 claims
- 2250US2021369749A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2349US2006235007A1Substituted 1,4-diazepines and uses thereofLU TIANBAO·Filed 2006·Application pending·0 cites
- 2448US9249163B2PDE10a inhibitors for the treatment of type II diabetesJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Feb 2, 2016·0 cites·19 claims
- 2548US2006148792A1Substituted 1,4-benzodiazepines and uses thereofLU TIANBAO·Filed 2006·Application pending·0 cites
- 2648US2006189511A1Method for cytoprotection through mdm2 and hdm2 inhibitionKOBLISH HOLLY K·Filed 2003·Application pending·0 cites
- 2747US7612211B2Benzimidazole TRPV1 inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Nov 3, 2009·0 cites·27 claims
- 2846US7446210B2Factor Xa compoundsJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Nov 4, 2008·0 cites·13 claims
- 2942US2019248779A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3041US2020055844A14-sulfonylaminocarbonylquinoline derivatives for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3140US2019256474A1N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosisPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3240US2019248765A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3336US2012202856A1Substituted benzimdazole derivatives useful as trpm8 receptor modulatorsPLAYER MARK R·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel Parks files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →